Given that peritoneal metastasis frequently correlates with diffuse-type histology, it is notable that in both the SPOTLIGHT and GLOW trials, the OS benefit for patients with diffuse gastric cancer did not reach statistical significance in the prespecified subgroup analyses (SPOTLIGHT HR 0.76 [0.51–1.13]; GLOW HR 0.73 [0.49–1.07]).
← all excerpts
Molecular mechanisms of metastatic peritoneal dissemination in gastric adenocarcinoma.
1
—
—